Drug intelligence / Profile preview

HS-20110 + bevacizumab + oxaliplatin + 5-fluorouracil + leucovorin

Development stage: Unknown
Lead developer: Hansoh Pharmaceutical Group
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HS-20110 + bevacizumab + oxaliplatin + 5-fluorouracil + leucovorin is an investigational combination regimen being developed for the treatment of advanced colorectal cancer. The core investigational component, HS-20110, is a humanized antibody-drug conjugate (ADC) targeting Cadherin-17 (CDH17), a cell adhesion protein frequently overexpressed in gastrointestinal cancers. HS-20110 consists of an anti-CDH17 monoclonal antibody conjugated to a topoisomerase inhibitor (TOPOi) payload, designed to deliver cytotoxic effects specifically to tumor cells. This ADC is combined with bevacizumab, an anti-angiogenic monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), and the FOLFOX chemotherapy backbone (oxaliplatin, 5-fluorouracil, and leucovorin). The combination is currently being evaluated in Phase Ib/II clinical trials by Hansoh Pharmaceutical to assess safety, tolerability, and efficacy in patients with advanced colorectal cancer, particularly those with non-MSI-H and BRAF V600E wild-type status.

Other names: HS-20110 + bevacizumab + FOLFOX

Targets

TS (Thymidylate synthase)DNACDH17 (Cadherin-17)TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on HS-20110 + bevacizumab + oxaliplatin + 5-fluorouracil + leucovorin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-20110 + bevacizumab + oxaliplatin + 5-fluorouracil + leucovorin.

Explore the full profile